Rubicon Technology (RBCN) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 30, 2022
Document Information Line Items
Entity Registrant Name	RUBICON TECHNOLOGY, INC.
Trading Symbol	RBCN
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		2,446,652
Amendment Flag	false
Entity Central Index Key	0001410172
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-33834
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4419301
Entity Address, Address Line One	900 East Green Street
Entity Address, City or Town	Bensenville
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60106
City Area Code	(847)
Local Phone Number	295-7000
Title of 12(b) Security	Common Stock, par value $.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 10,764	$ 11,260
Short-term investments	15,813	14,751
Accounts receivable, net	406	719
Inventories	611	658
Other inventory supplies	135	133
Prepaid expenses and other current assets	158	167
Assets held for sale	529	529
Total current assets	28,416	28,217
Inventories, non-current	457	468
Property and equipment, net	2,271	2,301
Total assets	31,144	30,986
Liabilities and stockholders’ equity
Accounts payable	292	545
Accrued payroll	496	426
Accrued and other current liabilities	52	220
Corporate income and franchise taxes	308	327
Accrued real estate taxes	97	78
Advance payments		2
Total current liabilities	1,245	1,598
Total liabilities	1,245	1,598
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $.001 par value, 1,000,000 undesignated shares authorized, no shares issued or outstanding
Common stock, $.001 par value, 8,200,000 shares authorized; 2,995,680 and 2,995,680 shares issued; 2,446,652 and 2,446,652 shares outstanding, respectively	29	29
Additional paid-in capital	376,658	376,640
Treasury stock, at cost, 549,028 and 549,028 shares	(15,147)	(15,147)
Accumulated other comprehensive loss	(2)	(1)
Accumulated deficit	(331,639)	(332,133)
Total stockholders’ equity	29,899	29,388
Total liabilities and stockholders’ equity	$ 31,144	$ 30,986

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	8,200,000	8,200,000
Common stock, shares issued	2,995,680	2,995,680
Common stock, shares outstanding	2,446,652	2,446,652
Treasury stock, shares	549,028	549,028

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 972	$ 495
Cost of goods sold	580	387
Gross profit	392	108
Operating expenses:
General and administrative	504	752
Sales and marketing	40	70
Gain on sale or disposal of assets	(432)
Other gain	(189)
Income (loss) from continuing operations	469	(714)
Other income:
Interest income	4	2
Unrealized gain on equity investments	7
Total other income	11	2
Income (loss) before income taxes from continuing operations	480	(712)
Income tax expense
Income (loss) from continuing operations	480	(712)
Income (loss) from operations of discontinued operations, net of taxes	14	(95)
Net income (loss)	$ 494	$ (807)
Net income (loss) per common share: basic
Continuing operations (in Dollars per share)	$ 0.2	$ (0.29)
Discontinued operations (in Dollars per share)	0.01	(0.04)
Net income (loss) per common share: diluted
Continuing operations (in Dollars per share)	0.2	(0.29)
Discontinued operations (in Dollars per share)	$ 0.01	$ (0.04)
Weighted average common shares outstanding used in computing net income (loss) per common share
Basic (in Shares)	2,446,652	2,430,555
Diluted (in Shares)	2,447,484	2,430,555

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Income (loss) from continuing operations	$ 480	$ (712)
Income (loss) from discontinued operations	14	(95)
Net income (loss)	494	(807)
Other comprehensive income (loss):
Unrealized loss on investments	(1)
Comprehensive income (loss)	$ 493	$ (807)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($) $ in Thousands	Common Stock	Treasury stock	Additional paid-in capital	Accum other comp loss	Accum deficit	Total
Balance at Dec. 31, 2020	$ 29	$ (15,147)	$ 376,456		$ (331,403)	$ 29,935
Balance (in Shares) at Dec. 31, 2020	2,971,283	(549,028)
Stock-based compensation			341			341
Common stock issued, net of shares withheld for employee taxes			(162)			(162)
Common stock issued, net of shares withheld for employee taxes (in Shares)	16,600
Net income (loss)					(807)	(807)
Balance at Mar. 31, 2021	$ 29	$ (15,147)	376,635		(332,210)	29,307
Balance (in Shares) at Mar. 31, 2021	2,987,883	(549,028)
Balance at Dec. 31, 2021	$ 29	$ (15,147)	376,640	(1)	(332,133)	29,388
Balance (in Shares) at Dec. 31, 2021	2,995,680	(549,028)
Stock-based compensation			18			18
Unrealized loss on investments, net of tax				(1)		(1)
Net income (loss)					494	494
Balance at Mar. 31, 2022	$ 29	$ (15,147)	$ 376,658	$ (2)	$ (331,639)	$ 29,899
Balance (in Shares) at Mar. 31, 2022	2,995,680	(549,028)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Income (loss) from continuing operations	$ 480	$ (712)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) continuing operations
Depreciation and amortization	30	38
Gain on sale or disposal of assets	(432)
Other gain	(189)
Stock-based compensation	18	341
Unrealized gain on equity investments, net	(7)
Changes in operating assets and liabilities:
Accounts receivable	306	50
Inventories	58	36
Other inventory supplies	(2)	1
Prepaid expenses and other assets	9	34
Accounts payable	(134)	(202)
Accrued payroll	69	(58)
Accrued real estate taxes	20	19
Corporate income and franchise taxes	(19)	22
Advanced payments	(1)	(8)
Accrued and other current liabilities	(76)	186
Net cash provided by (used in) continuing operations	130	(253)
Cash flows used in discontinued operations		(144)
Cash flows from investing activities
Purchase of property and equipment
Proceeds from sale or disposal of assets	432
Purchases of investments	(1,061)	(1)
Proceeds from sale of investments	3	1
Net cash used in investing activities	(626)
Cash flows from financing activities
Taxes paid related to net share settlement of equity awards		(162)
Net cash used in financing activities		(162)
Net decrease in cash & cash equivalents	(496)	(559)
Cash, cash equivalents and restricted cash, beginning of period	11,260	11,130
Cash, cash equivalents and restricted cash, end of period	$ 10,764	$ 10,571

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION Interim financial data The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete consolidated financial statements and should be read in conjunction with Rubicon Technology, Inc.’s (the “Company”) annual report filed on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair presentation of the results of operations have been included. Consolidated operating results for the three month period ended March 31, 2022, are not necessarily indicative of results that may be expected for the year ending December 31, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, Rubicon Worldwide LLC, doing business as Rubicon Technology Worldwide LLC, Rubicon Technology BP LLC, and the discontinued operations of Rubicon DTP LLC. In June 2021, the operations of Rubicon DTP LLC were discontinued. All intercompany transactions and balances have been eliminated in consolidation. Investments We invest our available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity-related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded in other income (expenses), in the Consolidated Statements of Operations. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support the current operations are classified as short-term. The Company reviews its available-for-sale debt securities investments at the end of each quarter for other-than-temporary declines in fair value based on the specific identification method. The Company considers various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, changes in underlying credit ratings, forecasted recovery, its ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. When the Company concludes that an other-than-temporary impairment has resulted, the difference between the fair value and carrying value is written off and recorded as a charge on the Consolidated Statements of Operations. Accounts receivable The majority of the Company’s accounts receivable is due from defense subcontractors, industrial manufacturers, fabricators, and resellers. Credit is extended based on an evaluation of the customer’s financial condition. Accounts receivable are due based on contract terms and at stated amounts due from customers, net of an allowance for doubtful accounts. Losses from credit sales are provided for in the financial statements. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including length of time customer’s account is past due, customer’s current ability to pay and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they are deemed uncollectible and such write-offs, net of payments received, are recorded as a reduction to the allowance. Purchases of Equity Securities by the Issuer and Affiliated Purchasers In November 2018, the Company’s Board of Directors authorized a program to repurchase up to $3,000,000 of its common stock. In July 2020, the Company used all of the original authorized $3,000,000. On December 14, 2020, Rubicon’s Board of Directors authorized an additional $3,000,000 for the repurchase of the Company’s common stock. The Company’s share repurchase program does not obligate it to acquire any specific number of shares. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time, through solicited or unsolicited transactions in the open market, in privately negotiated transactions or pursuant to a Rule 10b5-1 plan. The program may be terminated, suspended or modified at any time. There can be no assurance as to the number of shares of common stock repurchased. The Company records treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. No shares of the Company’s common stock were repurchased during the three months ended March 31, 2022. The dollar value of shares that may yet be purchased under the program is $3,000,000. Inventories Inventories are valued at the lower of cost or net realizable value. Net realizable value is determined based on an estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. Raw materials cost is determined using the first-in, first-out method, and work-in-process and finished goods costs are determined on a standard cost basis, which includes materials, labor and manufacturing overhead. The Company reduces the carrying value of its inventories for differences between the cost and the estimated net realizable value, taking into account usage, expected demand, technological obsolescence and other information. The Company establishes inventory reserves when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based on customer specifications. The Company evaluates the ability to realize the value of its inventory based on a combination of factors, including forecasted sales, estimated current and future market value and changes in customers’ product specifications. The Company’s method of estimating excess and obsolete inventory has remained consistent for all periods presented. Inventories of continuing operations consisted of the following: March 31, December 31, (in thousands) Raw materials $ 457 $ 468 Work-in-process 323 328 Finished goods 288 330 $ 1,068 $ 1,126 Discontinued operations had no inventories as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022 and December 31, 2021, the Company made the determination that raw material inventories were such that the likelihood of significant usage within the current year was doubtful and classified such raw material inventories as non-current in the reported financial statements. Property and equipment Property and equipment consisted of the following: March 31, 2022 December 31, 2021 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,296 Buildings 1,711 1,711 Information systems 819 819 Land and land improvements 594 594 Furniture and fixtures 7 7 Total cost 6,427 6,427 Accumulated depreciation and amortization (4,156 ) (4,126 ) Property and equipment, net $ 2,271 $ 2,301 Discontinued operations had no property and equipment as of March 31, 2022 and December 31, 2021, respectively. Assets held for sale and long-lived assets When circumstances, such as adverse market conditions, indicate that the carrying value of a long-lived asset may be impaired, the Company performs an analysis to review the recoverability of the asset’s carrying value. The Company makes estimates of the undiscounted cash flows (excluding interest charges) from the expected future operations of the asset. These estimates consider factors such as expected future operating income, operating trends and prospects, as well as the effects of demand, competition and other factors. If the analysis indicates that the carrying value is not recoverable from future cash flows, an impairment loss is recognized to the extent that the carrying value exceeds the estimated fair value. The estimated fair value of assets is determined using appraisal techniques, which assume the highest and best use of the asset by market participants, considering the use of the asset that is physically possible, legally permissible and financially feasible at the measurement date. Any impairment losses are recorded as operating expenses which reduce net income. For the year ended December 31, 2021, the Company reviewed the current fair value of its assets and concluded no adjustments were needed. Additionally, no adjustments were recorded for the three months ended March 31, 2022. The Company will continue to assess its long-lived assets to ensure the carrying amount of these assets is still appropriate given any changes in the asset usage, marketplace and other factors used in determining the current fair value. The Company completed a sale of excess consumable assets in the amount of approximately $432,000 during the three months ended March 31, 2022. On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date. Revenue recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts with Customers The Company does not provide maintenance or other services and it does not have sales that involve bill & hold arrangements, multiple elements or deliverables. However, the Company does provide product warranty for up to 90 days, for which the Company has accrued a warranty reserve of $1,000 and $1,000 at March 31, 2022 and December 31, 2021, respectively. Net income (loss) per common share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of diluted common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted-average shares (a) any outstanding stock options based on the treasury stock method and (b) restricted stock units (“RSU”). Basic and diluted net income (loss) per common share for the three months ended March 31, 2022 and 2021, were $.20 and $(.29) respectively. The Company had outstanding options exercisable into 4,050 and 19,500 shares of the Company’s common stock that would not have had a material effect at March 31, 2022 and would have been anti-dilutive at March 31, 2021. New accounting pronouncements adopted The Company has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact the Company’s consolidated financial statements and related disclosures.

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	3. INVESTMENTS The Company invests its available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, equity-related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income/(loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded in other income (expense), in the consolidated statements of operations. The following table presents the amortized cost and gross unrealized losses on all securities at March 31, 2022: Amortized Gross Gross Fair (in thousands) Short-term investments: U.S. Treasury securities $ 14,752 $ - $ - $ 14,752 Marketable securities 1,054 7 - 1,061 Total short-term investments $ 15,806 $ 7 $ - $ 15,813 The following table presents the amortized cost and gross unrealized losses on all securities at December 31, 2021: Amortized Gross Gross Fair (in thousands) Short-term investments: U.S. Treasury securities $ 14,751 $ - $ - $ 14,751 Total short-term investments $ 14,751 $ - $ - $ 14,751 The Company values its investments at fair value, defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s fixed-income available-for-sale debt securities consist of U.S. Treasury securities, high-quality investment grade commercial paper, FDIC guaranteed certificates of deposit, equity-related securities and corporate notes. The Company values these securities based on pricing from pricing vendors, who may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. The valuation techniques used to measure the fair value of the Company’s financial instruments having Level 2 inputs were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models, such as discounted cash flow techniques. The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2022: Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,082 $ - $ - $ 3,082 Investments: Available-for-sale securities — current: U.S. Treasury securities - 14,752 - 14,752 Marketable securities 1,061 1,061 Total $ 4,143 $ 14,752 $ - $ 18,895 The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2021: Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,137 $ - $ - $ 3,137 Investments: Available-for-sale securities — current: U.S. Treasury securities - 14,751 - 14,751 Total $ 3,137 $ 14,751 $ - $ 17,888 There are no terms or conditions restricting the Company from redeeming any of its investments. In addition to the debt securities noted above, the Company had approximately $7,700,000 and $8,100,000 of time deposits included in cash and cash equivalents as of March 31, 2022 and December 31, 2021, respectively.

Discontinued Operations_ Closur

Discontinued Operations: Closure of Direct Dose Rx	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS: Closure of Direct Dose Rx	4. DISCONTINUED OPERATIONS: Closure of Direct Dose Rx On June 24, 2021, the Company’s Board of Directors decided to close its pharmacy operations, Rubicon DTP LLC, doing business as Direct Dose Rx. Immediately thereafter, Direct Dose Rx began transitioning its customers to other providers and began the process of closing its operations. Direct Dose was launched as a start-up pharmacy primarily to deliver medications and vitamins to patients being discharged from skilled nursing facilities. Based on the Company’s review and analysis of ASC 205-20 Presentation of Discontinued Operations it concluded to present the discontinued operations separately. Three months ended 2022 2021 (in thousands) Revenues (discontinued operations) $ 0 $ 234 Operating (income) expense (discontinued operations) $ (14 ) $ 329 Income (loss) from discontinued operations, net of taxes $ 14 $ (95 )

Significant Customers

Significant Customers	3 Months Ended
	Mar. 31, 2022
Significant Customers Disclosure [Abstract]
SIGNIFICANT CUSTOMERS	5. SIGNIFICANT CUSTOMERS For the three months ended March 31, 2022, the Company had six customers individually that accounted for approximately 18%, 14%, 13%, 11%, 11% and 10% of revenue. For the three months ended March 31, 2021, the Company had four customers individually that accounted for approximately 28%, 22%, 17% and 12% of revenue. No other customer accounted for 10% or more of the Company’s revenues during the three months ended March 31, 2022 and 2021. We expect our sales to continue to be concentrated among a small number of customers. However, we also expect that our significant customers may change from time to time. Customers individually representing more than 10% of trade receivables accounted for approximately 55% and 80% of accounts receivable as of March 31, 2022 and December 31, 2021, respectively.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	6. STOCKHOLDERS’ EQUITY Common shares reserved As of March 31, 2022, the Company had reserved 4,050 and 28,030 shares of common stock for issuance upon the exercise of outstanding common stock options and vesting of RSUs, respectively. Also, 304,731 shares of the Company’s common stock were reserved for future grants of stock options and RSUs (or other similar equity instruments) under the Rubicon Technology, Inc. 2016 Stock Incentive Plan (the “2016 Plan”) as of March 31, 2022.

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK INCENTIVE PLANS	7. STOCK INCENTIVE PLANS In August 2007, the Company adopted the Rubicon Technology Inc. 2007 Stock Incentive Plan, which was amended and restated effective in March 2011 (the “2007 Plan”), and which allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance awards and bonus shares. The maximum number of shares that could be awarded under the 2007 Plan was 440,769 shares. Options granted under the 2007 Plan entitled the holder to purchase shares of the Company’s common stock at the specified option exercise price, which could not be less than the fair value of the common stock on the grant date. On June 24, 2016, the plan terminated with the adoption of the Rubicon Technology, Inc. 2016 Stock Incentive Plan, (the “2016 Plan”). Any existing awards under the 2007 Plan remain outstanding in accordance with their current terms under the 2007 Plan. In June 2016, the Company’s stockholders approved adoption of the 2016 Plan effective as of March 17, 2016, which allows for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance awards and bonus shares. The Compensation Committee of the Board administers the 2016 Plan. The committee determines the type of award to be granted, the fair value, the number of shares covered by the award, and the time when the award vests and may be exercised. Pursuant to the 2016 Plan, 304,731 shares of the Company’s common stock plus any shares subject to outstanding awards under the 2007 Plan that subsequently expire unexercised, are forfeited without the delivery of shares or are settled in cash, will be available for issuance under the 2016 Plan. The 2016 Plan will automatically terminate on March 17, 2026, unless the Company terminates it sooner. The following table summarizes the activity of the stock incentive and equity plans as of March 31, 2022, and changes during the three months then ended: Shares available for grant Number of options outstanding Weighted- average exercise Number of restricted stock and board shares issued Number of RSUs outstanding At January 1, 2022 304,731 4,050 $ 14.16 99,570 28,030 Granted 0 0 0.00 0 0 Exercised/issued 0 0 0.00 0 0 Cancelled/forfeited 0 0 0.00 0 0 At March 31, 2022 304,731 4,050 $ 14.16 99,570 28,030 The Company’s aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock. Based on the fair value of the common stock at March 31, 2022, there was $8,095 of intrinsic value arising from 3,250 in the money stock options exercisable and outstanding. The Company uses the Black-Scholes option pricing model to value stock options. The Company uses historical stock price average to determine its volatility assumptions. The assumed risk-free rates were based on U.S. Treasury rates in effect at the time of grant with a term consistent with the expected option lives. The expected term is based upon the vesting term of the Company’s options. The stock compensation expense was allocated using the straight-line method. As of September 2020, all options had had been fully expensed. As such, there is no stock compensation expense or unrecognized compensation expense related to stock options as of March 31, 2022 and 2021. As of March 31, 2022, and December 31, 2021, the Company did not have any non-vested options. The Company used Monte Carlo simulation model valuation technique to determine the fair value of RSUs granted because the awards vest based upon achievement of market price targets. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award and calculates the fair value of each RSU. Compensation expense related to the RSUs is recognized by the Company over a service period that was derived from the statistical valuation methods used to estimate the fair value of the RSUs at grant date. During the three months ended March 31, 2022 and 2021, the Company recorded $18,417 and $0, respectively, in RSU expense related to employee compensation. The Company’s board of directors are compensated partially in cash and partially in RSUs. For the three months ended March 31, 2022 and 2021, the Company recorded $7,500 and $7,500, respectively, of stock compensation expense related to RSUs granted to the board of directors. A summary of the Company’s RSUs for the three month period ended March 31, 2022 is presented below: RSUs outstanding Weighted Aggregate value Non-vested RSUs as of January 1, 2022 28,030 $ 9.29 Granted 0 0.00 Vested 0 0.00 Cancelled 0 0.00 Non-vested RSUs at March 31, 2022 28,030 $ 9.29 $ 260,399 For the three months ended March 31, 2022, the Company did not recognize any expense for the granting of shares to employees of the Company as a bonus. For the three months ended March 31, 2021, the Company awarded approximately 32,000 shares to an officer of the Company with a fair market value of approximately $341,000.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company experiences routine litigation in the normal course of its business. The management of the Company does not believe any pending litigation, will have a material adverse effect on the financial condition, results of operations or cash flows of the Company. COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. The magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in a material impact to the Company’s financial statements in future reporting periods.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”) which, among other provisions, reduced the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. The SEC issued guidance, Staff Accounting Bulletin 118, on accounting for the tax effects of the Act. The guidance allows the Company to record provisional amounts for those impacts, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. The Company has completed its accounting for the tax effects of enactment of the Act. The deemed inclusion from the repatriation tax increased from $3,900,000 at the time of provision to $5,000,000 at the time the calculation was finalized for the tax return. The increase of the inclusion related primarily to the refinement of Malaysia earnings and profits. As the Company is in a full valuation allowance position, an equal benefit adjustment was recorded for the impact of the increase of the deemed repatriation tax. The Company is subject to taxation in the U.S. and in U.S. state jurisdictions. On a quarterly basis, the Company assesses the recoverability of deferred tax assets and the need for a valuation allowance. Such evaluations involve the application of significant judgment, and multiple factors, both positive and negative, are considered. For the period ended March 31, 2022, a valuation allowance has been included in the 2021 forecasted effective tax rate. The Company is in a cumulative loss position for the past three years, which is considered significant negative evidence that is difficult to overcome on a “more likely than not” standard through objectively verifiable data. Under the accounting standards, objective verifiable evidence is given greater weight than subjective evidence such as the Company’s projections for future growth. Based on an evaluation in accordance with the accounting standards, as of December 31, 2015, a valuation allowance has been recorded against the net U.S. deferred tax assets in order to measure only the portion of the deferred tax assets that are more likely than not to be realized based on the weight of all available evidence. At March 31, 2022, the Company continues to be in a three-year cumulative loss position, therefore, until an appropriate level of profitability is attained, the Company expects to maintain a full valuation allowance on its U.S. net deferred tax assets. Any U.S. tax benefits or tax expense recorded on the Company’s consolidated statements of operations will be offset with a corresponding adjustment from the use of the net operating loss (“NOL”) carry-forward asset which currently has a full valuation allowance. In the event that the Company changes its determination as to the amount of deferred tax assets that can be realized, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	10. SEGMENT INFORMATION The Company has determined that it operates in two segments, the sapphire and pharmacy (until June 2021) businesses. The tables below include only information related to the continuing operations of the Company’s sapphire business. Revenue is attributed by geographic region based on ship-to location of the Company’s customers. The following table summarizes revenue by geographic region: Three months ended 2022 2021 (in thousands) North America $ 768 $ 354 Asia 193 139 Other 11 2 Total revenue $ 972 $ 495 For the three months ended March 31, 2022 and 2021, all revenues from continuing operations were from the sale of optical sapphire products. Substantially all of the Company’s assets are located in the United States.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, Rubicon Worldwide LLC, doing business as Rubicon Technology Worldwide LLC, Rubicon Technology BP LLC, and the discontinued operations of Rubicon DTP LLC. In June 2021, the operations of Rubicon DTP LLC were discontinued. All intercompany transactions and balances have been eliminated in consolidation.
Investments	Investments We invest our available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity-related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded in other income (expenses), in the Consolidated Statements of Operations. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support the current operations are classified as short-term. The Company reviews its available-for-sale debt securities investments at the end of each quarter for other-than-temporary declines in fair value based on the specific identification method. The Company considers various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, changes in underlying credit ratings, forecasted recovery, its ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. When the Company concludes that an other-than-temporary impairment has resulted, the difference between the fair value and carrying value is written off and recorded as a charge on the Consolidated Statements of Operations.
Accounts receivable	Accounts receivable The majority of the Company’s accounts receivable is due from defense subcontractors, industrial manufacturers, fabricators, and resellers. Credit is extended based on an evaluation of the customer’s financial condition. Accounts receivable are due based on contract terms and at stated amounts due from customers, net of an allowance for doubtful accounts. Losses from credit sales are provided for in the financial statements. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including length of time customer’s account is past due, customer’s current ability to pay and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they are deemed uncollectible and such write-offs, net of payments received, are recorded as a reduction to the allowance.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers	Purchases of Equity Securities by the Issuer and Affiliated Purchasers In November 2018, the Company’s Board of Directors authorized a program to repurchase up to $3,000,000 of its common stock. In July 2020, the Company used all of the original authorized $3,000,000. On December 14, 2020, Rubicon’s Board of Directors authorized an additional $3,000,000 for the repurchase of the Company’s common stock. The Company’s share repurchase program does not obligate it to acquire any specific number of shares. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time, through solicited or unsolicited transactions in the open market, in privately negotiated transactions or pursuant to a Rule 10b5-1 plan. The program may be terminated, suspended or modified at any time. There can be no assurance as to the number of shares of common stock repurchased. The Company records treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. No shares of the Company’s common stock were repurchased during the three months ended March 31, 2022. The dollar value of shares that may yet be purchased under the program is $3,000,000.
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value. Net realizable value is determined based on an estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. Raw materials cost is determined using the first-in, first-out method, and work-in-process and finished goods costs are determined on a standard cost basis, which includes materials, labor and manufacturing overhead. The Company reduces the carrying value of its inventories for differences between the cost and the estimated net realizable value, taking into account usage, expected demand, technological obsolescence and other information. The Company establishes inventory reserves when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based on customer specifications. The Company evaluates the ability to realize the value of its inventory based on a combination of factors, including forecasted sales, estimated current and future market value and changes in customers’ product specifications. The Company’s method of estimating excess and obsolete inventory has remained consistent for all periods presented. Inventories of continuing operations consisted of the following: March 31, December 31, (in thousands) Raw materials $ 457 $ 468 Work-in-process 323 328 Finished goods 288 330 $ 1,068 $ 1,126 Discontinued operations had no inventories as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022 and December 31, 2021, the Company made the determination that raw material inventories were such that the likelihood of significant usage within the current year was doubtful and classified such raw material inventories as non-current in the reported financial statements.
Property and equipment	Property and equipment Property and equipment consisted of the following: March 31, 2022 December 31, 2021 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,296 Buildings 1,711 1,711 Information systems 819 819 Land and land improvements 594 594 Furniture and fixtures 7 7 Total cost 6,427 6,427 Accumulated depreciation and amortization (4,156 ) (4,126 ) Property and equipment, net $ 2,271 $ 2,301 Discontinued operations had no property and equipment as of March 31, 2022 and December 31, 2021, respectively.
Assets held for sale and long-lived assets	Assets held for sale and long-lived assets When circumstances, such as adverse market conditions, indicate that the carrying value of a long-lived asset may be impaired, the Company performs an analysis to review the recoverability of the asset’s carrying value. The Company makes estimates of the undiscounted cash flows (excluding interest charges) from the expected future operations of the asset. These estimates consider factors such as expected future operating income, operating trends and prospects, as well as the effects of demand, competition and other factors. If the analysis indicates that the carrying value is not recoverable from future cash flows, an impairment loss is recognized to the extent that the carrying value exceeds the estimated fair value. The estimated fair value of assets is determined using appraisal techniques, which assume the highest and best use of the asset by market participants, considering the use of the asset that is physically possible, legally permissible and financially feasible at the measurement date. Any impairment losses are recorded as operating expenses which reduce net income. For the year ended December 31, 2021, the Company reviewed the current fair value of its assets and concluded no adjustments were needed. Additionally, no adjustments were recorded for the three months ended March 31, 2022. The Company will continue to assess its long-lived assets to ensure the carrying amount of these assets is still appropriate given any changes in the asset usage, marketplace and other factors used in determining the current fair value. The Company completed a sale of excess consumable assets in the amount of approximately $432,000 during the three months ended March 31, 2022. On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date.
Revenue recognition	Revenue recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts with Customers The Company does not provide maintenance or other services and it does not have sales that involve bill & hold arrangements, multiple elements or deliverables. However, the Company does provide product warranty for up to 90 days, for which the Company has accrued a warranty reserve of $1,000 and $1,000 at March 31, 2022 and December 31, 2021, respectively.
Net income (loss) per common share	Net income (loss) per common share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of diluted common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted-average shares (a) any outstanding stock options based on the treasury stock method and (b) restricted stock units (“RSU”). Basic and diluted net income (loss) per common share for the three months ended March 31, 2022 and 2021, were $.20 and $(.29) respectively. The Company had outstanding options exercisable into 4,050 and 19,500 shares of the Company’s common stock that would not have had a material effect at March 31, 2022 and would have been anti-dilutive at March 31, 2021.
New accounting pronouncements adopted	New accounting pronouncements adopted The Company has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact the Company’s consolidated financial statements and related disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of inventories	March 31, December 31, (in thousands) Raw materials $ 457 $ 468 Work-in-process 323 328 Finished goods 288 330 $ 1,068 $ 1,126
Schedule of property and equipment	March 31, 2022 December 31, 2021 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,296 Buildings 1,711 1,711 Information systems 819 819 Land and land improvements 594 594 Furniture and fixtures 7 7 Total cost 6,427 6,427 Accumulated depreciation and amortization (4,156 ) (4,126 ) Property and equipment, net $ 2,271 $ 2,301

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of amortized cost and gross unrealized losses on all securities	Amortized Gross Gross Fair (in thousands) Short-term investments: U.S. Treasury securities $ 14,752 $ - $ - $ 14,752 Marketable securities 1,054 7 - 1,061 Total short-term investments $ 15,806 $ 7 $ - $ 15,813 Amortized Gross Gross Fair (in thousands) Short-term investments: U.S. Treasury securities $ 14,751 $ - $ - $ 14,751 Total short-term investments $ 14,751 $ - $ - $ 14,751
Schedule of financial assets measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,082 $ - $ - $ 3,082 Investments: Available-for-sale securities — current: U.S. Treasury securities - 14,752 - 14,752 Marketable securities 1,061 1,061 Total $ 4,143 $ 14,752 $ - $ 18,895 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,137 $ - $ - $ 3,137 Investments: Available-for-sale securities — current: U.S. Treasury securities - 14,751 - 14,751 Total $ 3,137 $ 14,751 $ - $ 17,888

Discontinued Operations_ Clos_2

Discontinued Operations: Closure of Direct Dose Rx (Tables)	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	Three months ended 2022 2021 (in thousands) Revenues (discontinued operations) $ 0 $ 234 Operating (income) expense (discontinued operations) $ (14 ) $ 329 Income (loss) from discontinued operations, net of taxes $ 14 $ (95 )

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of summarizes the activity of the stock incentive and equity plans	Shares available for grant Number of options outstanding Weighted- average exercise Number of restricted stock and board shares issued Number of RSUs outstanding At January 1, 2022 304,731 4,050 $ 14.16 99,570 28,030 Granted 0 0 0.00 0 0 Exercised/issued 0 0 0.00 0 0 Cancelled/forfeited 0 0 0.00 0 0 At March 31, 2022 304,731 4,050 $ 14.16 99,570 28,030
Schedule of the company’s RSUs for the three month period ended	RSUs outstanding Weighted Aggregate value Non-vested RSUs as of January 1, 2022 28,030 $ 9.29 Granted 0 0.00 Vested 0 0.00 Cancelled 0 0.00 Non-vested RSUs at March 31, 2022 28,030 $ 9.29 $ 260,399

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of geographic region	Three months ended 2022 2021 (in thousands) North America $ 768 $ 354 Asia 193 139 Other 11 2 Total revenue $ 972 $ 495

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	Feb. 07, 2022	Jul. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 14, 2020	Nov. 30, 2018
Summary of Significant Accounting Policies (Details) [Line Items]
Repurchase of common stock			$ 3,000,000
Original authorized amount		$ 3,000,000
Sale of assets			$ 432,000
Net proceeds	$ 600,000
Warrant term			90 days
Warranty reserve			$ 1,000		$ 1,000
Basic net income (loss) per common share (in Dollars per share)			$ 0.20	$ (0.29)
Outstanding options exercisable shares (in Shares)			4,050	19,500
Illinois [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Real estate sale of land	$ 722,000
Board of Directors [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Repurchase of common stock						$ 3,000,000	$ 3,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of inventories - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule of inventories [Abstract]
Raw materials	$ 457	$ 468
Work-in-process	323	328
Finished goods	288	330
Inventories	$ 1,068	$ 1,126

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total cost	$ 6,427	$ 6,427
Accumulated depreciation and amortization	(4,156)	(4,126)
Property and equipment, net	2,271	2,301
Machinery, equipment and tooling [Member]
Property, Plant and Equipment [Line Items]
Total cost	3,296	3,296
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,711	1,711
Information systems [Member]
Property, Plant and Equipment [Line Items]
Total cost	819	819
Land and land improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	594	594
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	$ 7	$ 7

Investments (Details)

Investments (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 7,700,000	$ 8,100,000

Investments (Details) - Schedul

Investments (Details) - Schedule of amortized cost and gross unrealized losses on all securities - Short-term Investments [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
U.S. Treasury Securities [Member]
Investments (Details) - Schedule of amortized cost and gross unrealized losses on all securities [Line Items]
Amortized cost	$ 14,752	$ 14,751
Gross unrealized gains
Gross unrealized losses
Fair value	14,752	14,751
Marketable Securities [Member]
Investments (Details) - Schedule of amortized cost and gross unrealized losses on all securities [Line Items]
Amortized cost	1,054
Gross unrealized gains	7
Gross unrealized losses
Fair value	1,061
Total Short-term Investments [Member]
Investments (Details) - Schedule of amortized cost and gross unrealized losses on all securities [Line Items]
Amortized cost	15,806	14,751
Gross unrealized gains	7
Gross unrealized losses
Fair value	$ 15,813	$ 14,751

Investments (Details) - Sched_2

Investments (Details) - Schedule of financial assets measured at fair value on a recurring basis - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Available-for-sale securities — current:
Total		$ 17,888
Money market funds [Member]
Cash equivalents:
Cash equivalents	$ 3,082	3,137
U.S. Treasury securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current	14,752	14,751
Marketable securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current	1,061
Total	18,895
Level 1 [Member]
Available-for-sale securities — current:
Total		3,137
Level 1 [Member] | Money market funds [Member]
Cash equivalents:
Cash equivalents	3,082	3,137
Level 1 [Member] | U.S. Treasury securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current
Level 1 [Member] | Marketable securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current	1,061
Total	4,143
Level 2 [Member]
Available-for-sale securities — current:
Total		14,751
Level 2 [Member] | Money market funds [Member]
Cash equivalents:
Cash equivalents
Level 2 [Member] | U.S. Treasury securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current	14,752	14,751
Level 2 [Member] | Marketable securities [Member]
Available-for-sale securities — current:
Total	14,752
Level 3 [Member]
Available-for-sale securities — current:
Total
Level 3 [Member] | Money market funds [Member]
Cash equivalents:
Cash equivalents
Level 3 [Member] | U.S. Treasury securities [Member]
Available-for-sale securities — current:
Available-for-sale securities — current
Level 3 [Member] | Marketable securities [Member]
Available-for-sale securities — current:
Total

Discontinued Operations_ Clos_3

Discontinued Operations: Closure of Direct Dose Rx (Details) - Schedule of discontinued operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of discontinued operations [Abstract]
Revenues (discontinued operations)	$ 0	$ 234
Operating (income) expense (discontinued operations)	(14)	329
Income (loss) from discontinued operations, net of taxes	$ 14	$ (95)

Significant Customers (Details)

Significant Customers (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Significant Customers (Details) [Line Items]
Other customers revenues percentages	10.00%	10.00%
Trade Accounts Receivable [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	10.00%		10.00%
Trade Accounts Receivable [Member] | Customer individually [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	55.00%		80.00%
Sales Revenue, Net [Member] | Customer One [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	18.00%	28.00%
Sales Revenue, Net [Member] | Customer Two [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	14.00%	22.00%
Sales Revenue, Net [Member] | Customer Three [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	13.00%	17.00%
Sales Revenue, Net [Member] | Customer Four [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	11.00%	12.00%
Sales Revenue, Net [Member] | Customer Five [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	11.00%
Sales Revenue, Net [Member] | Customer Six [Member]
Significant Customers (Details) [Line Items]
Concentration risk percentage	10.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Mar. 31, 2022shares
Stockholders' Equity Note [Abstract]
Reserved common stock shares for issuance	4,050
Reserved common stock shares for outstanding	28,030
Common stock reserved for future grants	304,731

Stock Incentive Plans (Details)

Stock Incentive Plans (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Aug. 31, 2007
Stock Incentive Plans (Details) [Line Items]
Fair value of common stock	$ 8,095
Expense related to employee compensation	18,417		$ 0
Stock compensation expense	$ 7,500		$ 7,500
Share issued (in Shares)		32,000
Fair market value		$ 341,000
2007 Stock Incentive Plan [Member]
Stock Incentive Plans (Details) [Line Items]
Maximum number of shares awarded or sold (in Shares)				440,769
2016 Plan [Member]
Stock Incentive Plans (Details) [Line Items]
Common stock shares subject to outstanding (in Shares)	304,731
Plan termination date, description	The 2016 Plan will automatically terminate on March 17, 2026, unless the Company terminates it sooner.
Stock options [Member]
Stock Incentive Plans (Details) [Line Items]
Stock options exercisable and outstanding (in Shares)	3,250

Stock Incentive Plans (Detail_2

Stock Incentive Plans (Details) - Schedule of summarizes the activity of the stock incentive and equity plans	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Schedule of summarizes the activity of the stock incentive and equity plans [Abstract]
Shares available for grant, Beginning	304,731
Number of options outstanding, Beginning	4,050
Weighted-average option exercise price, Beginning (in Dollars per share) | $ / shares	$ 14.16
Number of restricted stock shares issued, Beginning	99,570
Number of RSUs outstanding, Beginning	28,030
Shares available for grant, Ending	304,731
Number of options outstanding, Ending	4,050
Weighted-average option exercise price, Ending (in Dollars per share) | $ / shares	$ 14.16
Number of restricted stock shares issued, Ending	99,570
Number of RSUs outstanding, Ending	28,030
Shares available for grant, Granted	0
Number of options outstanding, Granted	0
Weighted-average option exercise price, Granted (in Dollars per share) | $ / shares	$ 0
Number of restricted stock shares issued, Granted	0
Number of RSUs outstanding, Granted	0
Shares available for grant, Exercised/issued	0
Number of options outstanding, Exercised/issued	0
Weighted-average option exercise price, Exercised/issued (in Dollars per share) | $ / shares	$ 0
Number of restricted stock shares issued, Exercised/issued	0
Number of RSUs outstanding, Exercised/issued	0
Shares available for grant, Cancelled/forfeited	0
Number of options outstanding, Cancelled/forfeited	0
Weighted-average option exercise price, Cancelled/forfeited (in Dollars per share) | $ / shares	$ 0
Number of restricted stock shares issued, Cancelled/forfeited	0
Number of RSUs outstanding, Cancelled/forfeited	0

Stock Incentive Plans (Detail_3

Stock Incentive Plans (Details) - Schedule of the company’s RSUs for the three month period ended - Restricted Stock Units (RSUs) [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Stock Incentive Plans (Details) - Schedule of the company’s RSUs for the three month period ended [Line Items]
Non-vested RSUs outstanding, Beginning balance | shares	28,030
Weighted-average price at time of grant, Non-vested , Beginning balance | $ / shares	$ 9.29
Non-vested RSUs outstanding, Granted | shares	0
Weighted-average price at time of grant, Granted | $ / shares	$ 0
Non-vested RSUs outstanding, Vested | shares	0
Weighted-average price at time of grant, Vested | $ / shares	$ 0
Non-vested RSUs outstanding, Cancelled | shares	0
Weighted-average price at time of grant, Cancelled | $ / shares	$ 0
Non-vested RSUs outstanding, Ending balance | shares	28,030
Weighted-average price at time of grant, Non-vested, Ending balance | $ / shares	$ 9.29
Aggregate intrinsic value, Non-vested, Ending balance | $	$ 260,399

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Income Taxes (Details) [Line Items]
Maturity date	Jan. 1, 2018
Maximum [Member]
Income Taxes (Details) [Line Items]
U.S. corporate tax rate	35.00%
Repatriation tax	$ 5,000,000
Minimum [Member]
Income Taxes (Details) [Line Items]
U.S. corporate tax rate	21.00%
Repatriation tax	$ 3,900,000

Segment Information (Details) -

Segment Information (Details) - Schedule of geographic region - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 972	$ 495
North America [Member]
Segment Reporting Information [Line Items]
Total revenue	768	354
Asia [Member]
Segment Reporting Information [Line Items]
Total revenue	193	139
Other [Member]
Segment Reporting Information [Line Items]
Total revenue	$ 11	$ 2